561 related articles for article (PubMed ID: 33558665)
41. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
Smith MR; Thomas S; Gormley M; Chowdhury S; Olmos D; Oudard S; Feng FY; Rajpurohit Y; Urtishak K; Ricci DS; Rooney B; Lopez-Gitlitz A; Yu M; Wyatt AW; Li M; Attard G; Small EJ
Clin Cancer Res; 2021 Aug; 27(16):4539-4548. PubMed ID: 34112710
[TBL] [Abstract][Full Text] [Related]
42. Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Fukuokaya W; Iwatani K; Sakanaka K; Kurokawa G; Yanagisawa T; Sasaki H; Miki J; Shimomura T; Miki K; Hatano T; Endo K; Egawa S
Int J Clin Oncol; 2020 Mar; 25(3):479-485. PubMed ID: 31512007
[TBL] [Abstract][Full Text] [Related]
43. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
44. Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.
Cao B; Kim M; Reizine NM; Moreira DM
Eur Urol Oncol; 2023 Jun; 6(3):237-250. PubMed ID: 36682938
[TBL] [Abstract][Full Text] [Related]
45. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Oudard S; Hadaschik B; Saad F; Cella D; Basch E; Graff JN; Uemura H; Dibaj S; Li S; Brookman-May SD; De Porre P; Bevans KB; Trudeau JJ; Small EJ; Smith MR
Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
[TBL] [Abstract][Full Text] [Related]
46. Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients.
Sánchez JC; Picola N; Rodriguez-Vida A; Costa M; Castañeda DM; Márquez MP; Rodriguez JM; Gaya JM; Bravo A; Buisan O; Servian P; Suarez JF; Felip MM; Caparrós MJR; Asensio AA; Vilaseca A
Cancer Med; 2023 Dec; 12(24):21969-21977. PubMed ID: 38063364
[TBL] [Abstract][Full Text] [Related]
47. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
[TBL] [Abstract][Full Text] [Related]
48. Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Int J Clin Oncol; 2019 Jul; 24(7):842-847. PubMed ID: 30739263
[TBL] [Abstract][Full Text] [Related]
49. An up-to-date evaluation of darolutamide for the treatment of prostate cancer.
Moussa M; Lazarou L; Dellis A; Abou Chakra M; Papatsoris A
Expert Opin Pharmacother; 2021 Mar; 22(4):397-402. PubMed ID: 33135506
[No Abstract] [Full Text] [Related]
50. Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Scott LJ
Target Oncol; 2020 Dec; 15(6):791-799. PubMed ID: 33237495
[TBL] [Abstract][Full Text] [Related]
51. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.
Rozet F; Roumeguère T; Spahn M; Beyersdorff D; Hammerer P
World J Urol; 2016 Nov; 34(11):1505-1513. PubMed ID: 26988552
[TBL] [Abstract][Full Text] [Related]
52. Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
Liu Z; Zhang T; Ma Z; Zheng S; Chen J; Wu Z; Zheng X; Li X; Liu Z
Am J Clin Oncol; 2020 Apr; 43(4):288-297. PubMed ID: 31972568
[TBL] [Abstract][Full Text] [Related]
53. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial.
Uemura H; Matsushima H; Kobayashi K; Mizusawa H; Nishimatsu H; Fizazi K; Smith M; Shore N; Tammela T; Tabata KI; Matsubara N; Iinuma M; Uemura H; Oya M; Momma T; Kawakita M; Fukasawa S; Kobayashi T; Kuss I; Le Berre MA; Snapir A; Sarapohja T; Suzuki K
Int J Clin Oncol; 2021 Mar; 26(3):578-590. PubMed ID: 33226524
[TBL] [Abstract][Full Text] [Related]
55. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Hussain A; Tripathi A; Pieczonka C; Cope D; McNatty A; Logothetis C; Guise T
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):290-300. PubMed ID: 33028943
[TBL] [Abstract][Full Text] [Related]
56. Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study.
Wang Y; Liu C; Liu C; Lu Y; Ban L; Niu Y
J Med Econ; 2024; 27(1):361-369. PubMed ID: 38375556
[TBL] [Abstract][Full Text] [Related]
57. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
58. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial.
Smith MR; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Mohamed AF; Odom D; Bartsch J; Snapir A; Sarapohja T; Fizazi K
Eur J Cancer; 2021 Sep; 154():138-146. PubMed ID: 34273811
[TBL] [Abstract][Full Text] [Related]
59. Non-metastatic castration-resistant prostate cancer: the evolving treatment landscape and role of nurse specialists.
Hunnisett A; Victor D
Br J Nurs; 2022 May; 31(10):S4-S13. PubMed ID: 35648671
[TBL] [Abstract][Full Text] [Related]
60. Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice.
Bögemann M; Facchini G; Bauernhofer T; Cathomas R; Xylinas E; Tombal B
Ir J Med Sci; 2023 Dec; 192(6):2643-2651. PubMed ID: 36944842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]